Preservation solutions used during abdominal transplantation: Current status and outcomes

Table 4 Selected clinical studies involving pancreas preservation solutions

Ref.	Solution	Cases	Patient survival	Graft survival
UW solution vs HTK solution
Potdar et al[68]	UW vs HTK	33 (UW 17, HTK 16)	No diff (30 d)	No diff (30 d)
			(UW 100%, HTK 100%)	(UW 100%, HTK 94%)
Englesbe et al[69]	UW vs HTK	75 (UW 41, HTK 36)	No diff (90 d)	No diff (90 d)
			(UW 100%, HTK 100%)	(UW 90.2%, HTK 86%)
Schneeberger et al[70]	UW vs HTK	68 (UW 41, HTK 27)	No diff (6 mo)	No diff (6 mo)
			(100% UW and HTK 96.3%)	(90.2% UW, 85.2% HTK)
Becker et al[71]	UW vs HTK	95 (UW 47, HTK 48)	No diff (1 yr)	No diff (1 yr)
			(UW 89.4% and HTK 95.7%)	(UW 82.6%, HTK 85.4%)
Agarwal et al[72]	UW vs HTK	87 (UW 10, HTK 78)	No diff (1 yr)	No diff (1 yr)
			(UW 100% and HTK 93%)	(UW 100% and HTK 92%)
Alonso et al[74]	UW vs HTK	97 (UW 81, HTK 16)	No diff (3 yr)	No diff (3 yr)
UW solution vs CEL solution
Manrique et al[77]	UW vs CEL	72 (UW 44, HTK 28)	No diff (2 yr)	No diff (2 yr)
			(UW 94.7%, CEL 84.4%)	(UW 74.6%, CEL 77.4%)
Boggi et al[25]	UW vs CEL	100 (UW 50, HTK 50)	No diff (1 yr)	No diff (1 yr)
			(UW 98.0%, CEL 98.0%)	(UW 95.8%, CEL 95.9%)

Diff: Difference; UW: University of Wisconsin; CEL: Celsior; HTK: Histidine-tryptophan-ketoglutarate.